Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Total Current Liabilities (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Total Current Liabilities for 8 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities changed N/A to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $8.0 million for FY2025, N/A changed from the prior year.
  • Total Current Liabilities for Q4 2025 was $8.0 million at Actinium Pharmaceuticals, up from $6.8 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $10.6 million in Q4 2022, with the low at $3.9 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $7.4 million, with a median of $7.9 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities skyrocketed 99.28% in 2022, then decreased 20.08% in 2023.
  • Over 5 years, Total Current Liabilities stood at $6.8 million in 2021, then surged by 55.38% to $10.6 million in 2022, then decreased by 20.08% to $8.5 million in 2023, then dropped by 8.7% to $7.8 million in 2024, then grew by 2.76% to $8.0 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $8.0 million, $6.8 million, and $8.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.